Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918940 | 0.88 | ALDH1A1 (0.49) | ALDH1A1HPGDGAAMAPTMEN1 | |
| SCHEMBL10341831 | 0.83 | CYP3A4 (0.43) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL8564350 | 0.83 | CYP3A4 (0.43) | ALDH1A1HPGDMAPTMEN1LMNA | |
| SCHEMBL10697590 | 0.81 | CYP3A4 (0.42) | ALDH1A1HPGDMAPTMEN1LMNA | |
| SCHEMBL10341987 | 0.81 | PDIA6 (0.47) | ALDH1A1HPGDGAAMAPTMEN1 | |
| SCHEMBL10433969 | 0.79 | MAPT (0.42) | ALDH1A1HPGDGAAMAPTMEN1 | |
| SCHEMBL28399502 | 0.77 | THRB (0.41) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL9918941 | 0.77 | ALDH1A1 (0.43) | ALDH1A1HPGDGAAMAPTKMT2A | |
| SCHEMBL8567728 | 0.77 | CYP3A4 (0.49) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL10341851 | 0.77 | CYP3A4 (0.49) | ALDH1A1HPGDGAAMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681221-B1 | TRICYCLIC INHIBITORS OF KINASES | ABBVIE INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9334236-B2 | Lactam-based compounds with a urethane or urea functional group, and uses thereof | ISP INVESTMENTS INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334236-B2 | Lactam-based compounds with a urethane or urea functional group, and uses thereof | ISP INVESTMENTS INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-8710065-B2 | Tricyclic inhibitors of kinases | ABBVIE INC. (US) | 2014-04-29 | — | — | US | disclosed |
| CN-103703005-A | Tricyclic inhibitors of kinases | ABBOTT LAB | 2014-04-02 | — | — | CN | disclosed |
| EP-2681221-A1 | TRICYCLIC INHIBITORS OF KINASES | AbbVie Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012161812-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120149861-A1 | LACTAM-BASED COMPOUNDS WITH A URETHANE OR UREA FUNCTIONAL GROUP, AND USES THEREOF | ISP INVESTMENTS LLC | 2012-06-14 | — | — | US | disclosed |
| US-20120149861-A1 | LACTAM-BASED COMPOUNDS WITH A URETHANE OR UREA FUNCTIONAL GROUP, AND USES THEREOF | ISP INVESTMENTS LLC | 2012-06-14 | — | — | US | disclosed |
| WO-2011022457-A1 | LACTAM-BASED COMPOUNDS WITH A URETHANE OR UREA FUNCTIONAL GROUP, AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149861-A1 | LACTAM-BASED COMPOUNDS WITH A URETHANE OR UREA FUNCTIONAL GROUP, AND USES THEREOF | CUTA, PUF60, PAM | ALDH1A1 1456/4885HPGD 3532/4885GAA 3190/4885 |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | ALDH1A1 2764/4885HPGD 2475/4885GAA 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.